Optimising piperacillin/tazobactam dosing in paediatrics

International Journal of Antimicrobial Agents

Volumn 30, Issue 4, 2007, Pages 320-324

  Tornøe, Christoffer W ^a   Tworzyanski, Jeffrey J ^a   Imoisili, Menfo A ^a   Alexander, John J ^a   Korth Bradley, Joan M ^b   Gobburu, Jogarao V S ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b PFIZER INC   (United States)

Author keywords

Anti infectives; Paediatric dosing; Pharmacometric analysis

Indexed keywords

PIPERACILLIN PLUS TAZOBACTAM;

ARTICLE; BACTERIAL INFECTION; BODY WEIGHT; CHILD; CONTROLLED STUDY; DEMOGRAPHY; DRUG CLEARANCE; DRUG MEGADOSE; GROUPS BY AGE; HUMAN; KIDNEY FUNCTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; NONLINEAR SYSTEM; PEDIATRICS; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SIMULATION; SINGLE DRUG DOSE;

AGE FACTORS; ANTI-BACTERIAL AGENTS; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; COMPUTER SIMULATION; DEMOGRAPHY; DRUG LABELING; HUMANS; INFANT; METABOLIC CLEARANCE RATE; PENICILLANIC ACID; PIPERACILLIN; REGRESSION ANALYSIS; TISSUE DISTRIBUTION;

EID: 34548433348     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2007.05.014     Document Type: Article

References (8)

1. Guidance for Industry. Exposure-response relationships-study design, data analysis, and regulatory applications. Center for Drug Evaluation and Research, United States Food and Drug Administration. http://www.fda.gov/cder/guidance/5341fnl.pdf.[accessed 30 March 2007].
2. Bhattaram A.V., Booth B.P., Ramchandani R.P., et al. Impact of pharmacometrics on drug approvals and labeling decisions: a survey of 42 new drug applications. AAPS J 7 (2005) E503-E512
3. Bhattaram A.V., Bonapace C., Chilukuri D.M., et al. Impact of pharmacometric reviews on new drug approval and labeling decisions-a survey of 31 new drug applications submitted between 2005 and 2006. Clin Pharmacol Ther 81 (2007) 213-221
4. Reed M.D., Goldfarb J., Yamashita T.S., Lemon E., and Blumer J.L. Single-dose pharmacokinetics of piperacillin and tazobactam in infants and children. Antimicrob Agents Chemother 38 (1994) 2817-2826
5. Chartrand S.A., Christenson J.C., Wellman C.O., Jenkins E., Harrison C.J., and Muralidharan G. Piperacillin/tazobactam in pediatric patients with intra-abdominal infections. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Orlando, FL (4-7 October, 1994) A65 Abstract
6. Tjandramaga T.B., Mullie A., Verbesselt R., de Schepper B.J., and Verbist L. Piperacillin: human pharmacokinetics after intravenous and intramuscular administration. Antimicrob Agents Chemother 14 (1978) 829-837
7. Kearns G.L., Abdel-Rahman S.M., Alander S.W., Blowey D.L., Leeder J.S., and Kauffman R.E. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N Engl J Med 349 (2003) 1157-1167
8. ® (Piperacillin and Tazobactam for Injection) Label. Center for Drug Evaluation and Research, United States Food and Drug Administration. http://www.fda.gov/cder/foi/label/2006/050684s046lbl.pdf.[accessed 30 March 2007].